Andreas W Herling

Summary

Affiliation: Sanofi-Aventis Deutschland GmbH

Publications

  1. doi request reprint Reversal of visceral adiposity in candy-diet fed female Wistar rats by the CB1 receptor antagonist rimonabant
    A W Herling
    Therapeutic Department Metabolism, Sanofi Aventis Deutschland GmbH, Frankfurt, Germany
    Int J Obes (Lond) 32:1363-72. 2008
  2. doi request reprint Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats
    Andreas W Herling
    Therapeutic Department Metabolism, Pharmacology, H 821, Sanofi Aventis Deutschland GmbH, Industriepark Hoechst, 65926 Frankfurt Main, Germany
    Endocrinology 149:2557-66. 2008
  3. ncbi request reprint CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats
    Andreas W Herling
    Sanofi Aventis Deutschland GmbH, Industriepark Hoechst, 65926 Frankfurt Main, Germany
    Am J Physiol Endocrinol Metab 293:E826-32. 2007
  4. doi request reprint Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625
    Michaela Liebig
    Therapeutic Department Metabolism, Sanofi Aventis Deutschland GmbH, Frankfurt, Germany
    Obesity (Silver Spring) 18:1952-8. 2010
  5. ncbi request reprint Dysregulated pyruvate dehydrogenase complex in Zucker diabetic fatty rats
    Christoph M Schummer
    Sanofi Aventis Deutschland GmbH, Industriepark Hoechst, 65926 Frankfurt am Main, Germany
    Am J Physiol Endocrinol Metab 294:E88-96. 2008
  6. ncbi request reprint Muscle-type specific intramyocellular and hepatic lipid metabolism during starvation in wistar rats
    Claudia Neumann-Haefelin
    Aventis Pharma Deutschland, Frankfurt, Germany
    Diabetes 53:528-34. 2004
  7. doi request reprint Reversal of inflammation-induced impairment of glucose uptake in adipocytes by direct effect of CB1 antagonism on adipose tissue macrophages
    Alexandra Miranville
    Therapeutic Department Metabolism, Sanofi Aventis Deutschland GmbH, Frankfurt, Germany
    Obesity (Silver Spring) 18:2247-54. 2010
  8. doi request reprint Identification and synthesis of novel inhibitors of acetyl-CoA carboxylase with in vitro and in vivo efficacy on fat oxidation
    Stefanie Keil
    Sanofi Aventis Deutschland GmbH, R and D, Diabetes Division, Industriepark Hoechst, Building G 878, D 65926 Frankfurt am Main, Germany
    J Med Chem 53:8679-87. 2010
  9. doi request reprint Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes
    Ulrich Werner
    Sanofi Aventis Deutschland GmbH, Frankfurt am Main, Germany
    Regul Pept 164:58-64. 2010
  10. doi request reprint AVE8134, a novel potent PPARα agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats
    Hans Ludwig Schäfer
    Diabetes Division, Sanofi Aventis Deutschland GmbH, Frankfurt am Main, Germany
    Acta Pharmacol Sin 33:82-90. 2012

Collaborators

Detail Information

Publications18

  1. doi request reprint Reversal of visceral adiposity in candy-diet fed female Wistar rats by the CB1 receptor antagonist rimonabant
    A W Herling
    Therapeutic Department Metabolism, Sanofi Aventis Deutschland GmbH, Frankfurt, Germany
    Int J Obes (Lond) 32:1363-72. 2008
    ..The severity of obesity is often more determined by the distribution of fat depots rather than by body weight itself. Therefore, the effect of rimonabant on fat distribution pattern was investigated in female candy-fed Wistar rats...
  2. doi request reprint Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats
    Andreas W Herling
    Therapeutic Department Metabolism, Pharmacology, H 821, Sanofi Aventis Deutschland GmbH, Industriepark Hoechst, 65926 Frankfurt Main, Germany
    Endocrinology 149:2557-66. 2008
    ..When the amount of endogenous fat stores declined, rimonabant-induced increased energy expenditure was maintained by a re-increase in food intake...
  3. ncbi request reprint CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats
    Andreas W Herling
    Sanofi Aventis Deutschland GmbH, Industriepark Hoechst, 65926 Frankfurt Main, Germany
    Am J Physiol Endocrinol Metab 293:E826-32. 2007
    ..This oxidation is driven by persistently increased lipolysis from fat tissues, independently of reduced caloric intake, and might significantly contribute to the weight-reducing effect...
  4. doi request reprint Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625
    Michaela Liebig
    Therapeutic Department Metabolism, Sanofi Aventis Deutschland GmbH, Frankfurt, Germany
    Obesity (Silver Spring) 18:1952-8. 2010
    ..Combination of OLZ treatment with the CB1-antagonist AVE1625 attenuated body weight gain in rats...
  5. ncbi request reprint Dysregulated pyruvate dehydrogenase complex in Zucker diabetic fatty rats
    Christoph M Schummer
    Sanofi Aventis Deutschland GmbH, Industriepark Hoechst, 65926 Frankfurt am Main, Germany
    Am J Physiol Endocrinol Metab 294:E88-96. 2008
    ..Furthermore, the results clearly demonstrate a rapid reactivation of PDC in liver and muscle of lean and obese rats after a glucose load and show that PDC activity is significantly lower in obese ZDF rats...
  6. ncbi request reprint Muscle-type specific intramyocellular and hepatic lipid metabolism during starvation in wistar rats
    Claudia Neumann-Haefelin
    Aventis Pharma Deutschland, Frankfurt, Germany
    Diabetes 53:528-34. 2004
    ..Both mechanisms might prevent impairment of insulin signaling by maintaining low levels of LCACoAs. Hepatic palmitoleoyl-CoA might have a special role in lipid metabolism due to its unique dynamic profile during starvation...
  7. doi request reprint Reversal of inflammation-induced impairment of glucose uptake in adipocytes by direct effect of CB1 antagonism on adipose tissue macrophages
    Alexandra Miranville
    Therapeutic Department Metabolism, Sanofi Aventis Deutschland GmbH, Frankfurt, Germany
    Obesity (Silver Spring) 18:2247-54. 2010
    ..Thus, SR141716 ameliorated adipose tissue insulin resistance by direct action on AT-MP demonstrating a novel peripheral mode of action of CB1 antagonism...
  8. doi request reprint Identification and synthesis of novel inhibitors of acetyl-CoA carboxylase with in vitro and in vivo efficacy on fat oxidation
    Stefanie Keil
    Sanofi Aventis Deutschland GmbH, R and D, Diabetes Division, Industriepark Hoechst, Building G 878, D 65926 Frankfurt am Main, Germany
    J Med Chem 53:8679-87. 2010
    ..4m is a suitable tool compound for the elucidation of the pharmacological potential of ACC1/2 inhibition...
  9. doi request reprint Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes
    Ulrich Werner
    Sanofi Aventis Deutschland GmbH, Frankfurt am Main, Germany
    Regul Pept 164:58-64. 2010
    ..The efficacy/safety profile of Lixisenatide is currently being studied further in an extensive ongoing Phase III clinical study programme. This article reviews the preclinical pharmacological profile of Lixisenatide...
  10. doi request reprint AVE8134, a novel potent PPARα agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats
    Hans Ludwig Schäfer
    Diabetes Division, Sanofi Aventis Deutschland GmbH, Frankfurt am Main, Germany
    Acta Pharmacol Sin 33:82-90. 2012
    ..AVE8134 is a structurally novel potent PPARα agonist. The aim of this study is to investigate the efficacy of AVE8134 on lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats...
  11. ncbi request reprint Determinants of intramyocellular lipid concentrations in rat hindleg muscle
    Claudia Neumann-Haefelin
    Aventis Pharma Deutschland GmbH, Frankfurt, Germany
    Magn Reson Med 50:242-8. 2003
    ..Therefore, when using IMCL as a surrogate marker for insulin resistance, it is necessary to carefully compare results with age- and gender-matched controls, and to use identical conditions...
  12. doi request reprint Benzimidazole-carboxamides as potent and bioavailable stearoyl-CoA desaturase (SCD1) inhibitors from ligand-based virtual screening and chemical optimization
    Hans Matter
    Sanofi Aventis Deutschland GmbH, Research and Development, D 65926 Frankfurt am Main, Germany
    Bioorg Med Chem Lett 23:1817-22. 2013
    ..After oral administration to male ZDF rats, this compound significantly decreased the serum fatty acid desaturation index, thus providing conclusive evidence for SCD1 inhibition in vivo by SAR224...
  13. ncbi request reprint Acyl ureas as human liver glycogen phosphorylase inhibitors for the treatment of type 2 diabetes
    Thomas Klabunde
    Sanofi Aventis Deutschland GmbH, Scientific and Medical Affairs, D 65926 Frankfurt am Main, Germany
    J Med Chem 48:6178-93. 2005
    ..These findings are consistent with the inhibition of hepatic glycogenolysis and support the use of acyl ureas for the treatment of type 2 diabetes...
  14. ncbi request reprint Muscle type-specific fatty acid metabolism in insulin resistance: an integrated in vivo study in Zucker diabetic fatty rats
    Anja Beha
    Sanofi Aventis Deutschland, Frankfurt Main, Germany
    Am J Physiol Endocrinol Metab 290:E989-97. 2006
    ....
  15. ncbi request reprint The role of glucose 6-phosphate in mediating the effects of glucokinase overexpression on hepatic glucose metabolism
    Linda Härndahl
    School of Clinical Medical Sciences Diabetes, The University of Newcastle upon Tyne, Medical School, Newcastle upon Tyne, UK
    FEBS J 273:336-46. 2006
    ..It is suggested that the regulatory strength of pharmacological glucokinase activators on glycogen metabolism can be predicted from their effect on the Glc6P content...
  16. ncbi request reprint Characterization of adenosine-A1 receptor-mediated antilipolysis in rats by tissue microdialysis, 1H-spectroscopy, and glucose clamp studies
    Corinna Schoelch
    Aventis Pharma Deutschland, Frankfurt Main, Germany
    Diabetes 53:1920-6. 2004
    ..Furthermore, in ZF rats, ARA treatment caused an immediate improvement of peripheral insulin sensitivity measured by the euglycemic-hyperinsulinemic glucose clamp technique...
  17. pmc Inhibition of autophagic proteolysis by inhibitors of phosphoinositide 3-kinase can interfere with the regulation of glycogen synthesis in isolated hepatocytes
    Peter F Dubbelhuis
    Department of Biochemistry, Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands
    Biochem J 368:827-33. 2002
    ....
  18. ncbi request reprint Prolonged blood glucose reduction in mrp-2 deficient rats (GY/TR(-)) by the glucose-6-phosphate translocase inhibitor S 3025
    Andreas W Herling
    Aventis Pharma Deutschland GmbH, H 821 Pharmacology, 65926 Frankfurt am Main, Germany
    Biochim Biophys Acta 1569:105-10. 2002
    ..Targeting to mrp-2 resulted in a significantly prolonged reduction of blood glucose levels in GY/TR(-) rats after i.v. bolus administration of S 3025...